Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
The development adds further growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV.

The development adds further growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV.
According to the new deal, AstraZeneca will have access to Covid-19 vaccine manufacturing at Oxford Biomedica’s Oxbox facility.
The filing is based on non-clinical and clinical data for Paxlovid and also comprised data from the Phase II/III EPIC-HR…
The Covid-19 pandemic has put extra pressure on research for neglected tropical diseases, but developments continue
ByGemcovac became the first saRNA vaccine to obtain approval for use in humans in India.
This deal might comprise Omicron-adapted Covid-19 vaccines contingent on obtaining the US FDA authorisation.
The filing is based on data from six clinical trials in subjects of the age 18 years and above.
Seven of the ten hepatitis C therapies analysed were found to suppress the SARS-CoV-2 virus.
Thank you for subscribing to Pharmaceutical Technology